What is TIRmed Pharma?
TIRmed Pharma is a specialized biotechnology enterprise dedicated to the development of innovative oligonucleotide treatments. The company's flagship initiative involves a next-generation topical cream designed to treat mild to moderate eczema. Unlike traditional steroid-based interventions that often carry systemic side effects, TIRmed Pharma's solution focuses on reducing itch and promoting tissue regeneration without suppressing the broader immune system. Founded by Prof. Anna-Lena Spetz, the organization leverages deep scientific expertise to tackle the unmet needs in the inflammatory skin disease market. By bridging the gap between advanced molecular biology and practical dermatological care, the company is establishing a new standard for non-invasive, patient-centric therapeutic interventions.
How much funding has TIRmed Pharma raised?
TIRmed Pharma has raised a total of $630K across 1 funding round:
Other Financing Round
$630K
Other Financing Round (2020): $630K with participation from Almi Foretags
Key Investors in TIRmed Pharma
Almi Foretags
Almi is a state-owned Swedish firm that provides loans and venture capital to support the growth and development of small and medium-sized enterprises, emphasizing sustainable business practices.
What's next for TIRmed Pharma?
With the recent capital deployment, TIRmed Pharma is expected to scale its clinical trial operations and refine its manufacturing processes for its lead topical candidate. The strategic roadmap likely includes expanding the research team to support ongoing regulatory filings and exploring potential partnerships to facilitate market entry. As the company moves forward, the focus will remain on validating the long-term safety and efficacy of its oligonucleotide platform. This phase of growth is critical for establishing the company as a leader in the dermatology space, potentially paving the way for future licensing agreements or further institutional backing as they approach commercialization milestones.
See full TIRmed Pharma company page
